公开(公告)号：US20150050740A1

公开(公告)日：2015-02-19

申请号：US14385940

申请日：2013-02-21

Applicant: Institute of Microbiology, Chinese Academy of Sciences

Inventor： Tingyi Wen ,  Guoqiang Zhang ,  Aihua Deng

IPC: C12N15/70 ,  C12N1/20

CPC classification number: C12N15/70 ,  C12N1/20 ,  C12N9/1007 ,  C12N15/74 ,  C12N15/75 ,  C12R1/19 ,  C12Y201/01037

Abstract: The present invention discloses a method for introducing an exogenous DNA by overcoming the restriction modification barrier of the target bacterium. The method provided in the present invention comprises the steps of 1) co-expressing all DNA-methyltransferase-encoding genes in the genome of the target bacterium in E. coli in which the restriction modification system thereof has been deleted to obtain a recombinant bacterium A; 2) introducing an exogenous DNA molecule into the recombinant bacterium A for in vivo modification so as to obtain a methylation-modified exogenous DNA molecule; 3) introducing the methylation-modified exogenous DNA molecule into the target bacterium. The experiments of the invention have demonstrated that the invention has a high transformation efficiency compared to prior methods for enabling genetic manipulation by overcoming the restriction modification barrier of the bacterium.

Abstract translation: 本发明公开了通过克服目标细菌的限制性修饰屏障来引入外源DNA的方法。 本发明提供的方法包括以下步骤：1）在其缺失限制性修饰系统的大肠杆菌中共表达靶细菌基因组中的所有DNA-甲基转移酶编码基因，获得重组细菌A ; 2）将外源DNA分子引入用于体内修饰的重组细菌A中，以获得甲基化修饰的外源DNA分子; 3）将甲基化修饰的外源DNA分子引入目标细菌。 本发明的实验已经证明，与通过克服细菌的限制性修饰屏障进行遗传操作的现有方法相比，本发明具有高的转化效率。

公开(公告)号：US20150038548A1

公开(公告)日：2015-02-05

申请号：US13937213

申请日：2013-07-09

Applicant: Metheor Therapeutics Corporation

Inventor： Andrew Z. Sledziewski ,  Theodore deVos

IPC: C12N15/113

CPC classification number: C12N15/1137 ,  C12N2310/13 ,  C12N2310/33 ,  C12N2310/3341 ,  C12N2310/531 ,  C12Y201/01037

Abstract: Modified oligonucleotides comprising CpG sites, wherein the cytosine is replaced by cytosine analogs are provided as well as methods of making the oligonucleotides and their use in treating cancer, tumorigenesis and hyper-proliferative disorders.

Abstract translation: 提供了包含CpG位点的修饰的寡核苷酸，其中胞嘧啶被胞嘧啶类似物替代，以及制备寡核苷酸及其在治疗癌症，肿瘤发生和高增殖性疾病中的用途的方法。

公开(公告)号：US20240327835A1

公开(公告)日：2024-10-03

申请号：US18417527

申请日：2024-01-19

Applicant: The General Hospital Corporation

Inventor： Jeannie T. Lee ,  Anand Minajigi ,  Lieselot Carrette

IPC: C12N15/113 ,  C12N9/10 ,  C12N9/90 ,  C12Q1/6883

CPC classification number: C12N15/113 ,  C12N9/1007 ,  C12N9/90 ,  C12Q1/6883 ,  C12Y201/01037 ,  C12Y599/01002 ,  C12N2310/113 ,  C12N2310/14 ,  C12N2310/20 ,  C12N2310/3231 ,  C12N2310/531 ,  C12N2320/34 ,  C12Q2600/156

Abstract: Methods for reactivating genes on the inactive X chromosome that include administering one or both of a DNA methyltransferase (DNMT) Inhibitor and/or a topoisomerase inhibitor, e.g., etoposide and/or 5′-azacytidine (aza), optionally in combination with an inhibitor of XIST RNA and/or an Xist-interacting protein, e.g., a chromatin-modifying protein, e.g., a small molecule or an inhibitory nucleic acid (such as a small inhibitory RNA (siRNAs) or antisense oligonucleotide (ASO)) that targets XIST RNA and/or a gene encoding an Xist-interacting protein, e.g., a chromatin-modifying protein.

公开(公告)号：US12098215B2

公开(公告)日：2024-09-24

申请号：US16307621

申请日：2017-06-06

Applicant: NORTHWESTERN UNIVERSITY

Inventor： Milan Mrksich ,  Justin A. Modica

IPC: C07K16/46 ,  A61P19/02 ,  A61P35/00 ,  A61P37/00 ,  C07K16/32 ,  C12N9/18 ,  A61K39/00

CPC classification number: C07K16/46 ,  A61P19/02 ,  A61P35/00 ,  A61P37/00 ,  C07K16/32 ,  C12N9/18 ,  C12Y301/01074 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00 ,  C07K2319/61 ,  C12Y201/01037 ,  C12Y301/21002 ,  C12Y302/01021 ,  C12Y304/11018 ,  C12Y304/24024 ,  C12Y305/02006

Abstract: The disclosure provides constructs comprising a first fusion protein, a second fusion protein, and a linker, wherein the first fusion protein and the second fusion protein each include an affinity reagent and a reactive enzyme, and the linker includes a first and second functional groups specific for irreversibly inhibiting the first and second fusion protein reactive enzymes. The disclosure further provides a method including (a) contacting a first fusion protein including an affinity reagent and a reactive enzyme with a linker including a functional group specific for irreversibly inhibiting the first fusion protein reactive enzyme thereby coupling the first fusion protein and the linker, and (b) contacting a second fusion protein including an affinity reagent and a reactive enzyme with the linker, the linker including a functional group specific for irreversibly inhibiting the second fusion protein reactive enzyme thereby coupling the second fusion protein and the linker.

公开(公告)号：US12060588B2

公开(公告)日：2024-08-13

申请号：US17858758

申请日：2022-07-06

Applicant: Whitehead Institute for Biomedical Research

Inventor： Rudolf Jaenisch ,  X. Shawn Liu ,  Hao Wu

IPC: C12N9/22 ,  A61K35/30 ,  A61K35/33 ,  A61P3/10 ,  A61P9/00 ,  A61P9/10 ,  A61P9/12 ,  C12N9/10 ,  C12N15/11 ,  C12N15/86 ,  C12N15/90

CPC classification number: C12N9/22 ,  A61K35/30 ,  A61K35/33 ,  C12N9/1007 ,  C12N15/11 ,  C12N15/86 ,  C12N15/907 ,  C12Y201/01037 ,  C12N2310/20 ,  C12N2740/15031 ,  C12N2800/80

Abstract: The invention relates to methods of modifying DNA methylation by contacting a cell with a catalytically inactive site specific nuclease fused to an effector domain having methylation or demethylation activity and one or more guide sequences.

公开(公告)号：US20240101623A1

公开(公告)日：2024-03-28

申请号：US18275151

申请日：2022-02-15

Applicant: Ospedale San Raffaele S.r.l. ,  Consiglio Nazionale Delle Ricerche

Inventor： Vania Broccoli ,  Alessandro Sessa

IPC: C07K14/47 ,  C12N9/10

CPC classification number: C07K14/4703 ,  C12N9/1007 ,  C12Y201/01037 ,  C07K2319/80

Abstract: An epigenetic silencer factor (ESF) comprising a transcription factor DNA-binding domain operably linked to at least one epigenetic effector domain, wherein the transcription factor is an oncogenic transcription factor or a cancer-associated transcription factor.

公开(公告)号：US20230340471A1

公开(公告)日：2023-10-26

申请号：US17963631

申请日：2022-10-11

Applicant: Ospedale San Raffaele S.R.L. ,  Fondazione Telethon

Inventor： Luigi Naldini ,  Angelo Leone Lombardo ,  Angelo Amabile ,  Alessandro Migliara

IPC: C12N15/113 ,  C12N9/10 ,  C07K14/47 ,  A61K38/45 ,  A61K48/00 ,  A61K35/12 ,  A61K38/17 ,  C12N9/22

CPC classification number: C12N15/113 ,  C12N9/1007 ,  C07K14/4703 ,  C12Y201/01037 ,  C12Y201/01043 ,  A61K38/45 ,  A61K48/005 ,  A61K35/12 ,  A61K38/1709 ,  C12N9/22 ,  C07K2319/80 ,  C12N2740/16043 ,  C12N2310/20 ,  A61K38/00

Abstract: A product comprising two or more artificial transcription repressors (ATRs), or polynucleotides encoding therefor, selected from groups (a), (b), (c) or (d): (a) an ATR comprising a DNA-binding domain operably linked to a KRAB domain or homologue thereof; (b) an ATR comprising a DNA-binding domain operably linked to a DNMT3A, DNMT3B or DNMT1 domain or homologue thereof; (c) an ATR comprising a DNA-binding domain operably linked to a DNMT3L domain or homologue thereof; and (d) an ATR comprising a DNA-binding domain operably linked to a SETDB1 domain or homologue thereof, wherein at least two of the ATRs are selected from different groups (a), (b), (c) or (d).

公开(公告)号：US20230174978A1

公开(公告)日：2023-06-08

申请号：US17698912

申请日：2022-03-18

Applicant: FLAGSHIP PIONEERING INNOVATIONS V, INC.

Inventor： David Arthur Berry ,  Rahul Karnik ,  Laura Gabriela Lande

IPC: C12N15/113 ,  C12N9/22 ,  C12N15/63 ,  C12N15/85 ,  C12N15/87 ,  C12N15/90 ,  C12N9/00 ,  C12N9/10 ,  C12N9/80 ,  A61K35/12

CPC classification number: C12N15/113 ,  A61K35/12 ,  C12N9/00 ,  C12N9/22 ,  C12N9/80 ,  C12N9/1007 ,  C12N15/63 ,  C12N15/85 ,  C12N15/87 ,  C12N15/90 ,  C12N15/907 ,  C12Y201/01037 ,  C12Y201/01043 ,  C12Y305/01098 ,  A01K2217/056 ,  A01K2227/706 ,  A01K2267/0318 ,  C07K2319/00 ,  C07K2319/85 ,  C12N2310/14 ,  C12N2310/20

Abstract: The present disclosure provides compositions with a modulating gene expression and methods for modulating transcription.

公开(公告)号：US20180318350A1

公开(公告)日：2018-11-08

申请号：US15773783

申请日：2016-11-04

Applicant: Emory University ,  St. Jude Children's Hospital, Inc.

Inventor： Rafi AHMED ,  Benjamin YOUNGBLOOD

IPC: A61K35/17 ,  C12N9/10 ,  C12N5/0783 ,  C07K14/705 ,  A61P31/14 ,  A61P35/00 ,  C07K14/005

CPC classification number: A61K35/17 ,  A61P31/14 ,  A61P35/00 ,  C07K14/005 ,  C07K14/70596 ,  C12N5/0636 ,  C12N5/10 ,  C12N9/1007 ,  C12N2740/16033 ,  C12N2740/16111 ,  C12Y201/01037

Abstract: This disclosure relates to the genetic modification of DNMT3A gene in immune cells. In certain embodiments, the modified immune cells may be used in adoptive T cells therapies to enhance immune responses against cancer or chronic infections. In certain embodiments, the disclosure relates to deleting, changing, or inserting nucleotides within the DNMT3A gene in immune cells, e.g., human CD8 T cells, such that the DNMT3A gene product does not function for methylation. In certain embodiments, modification of the DNMT3A gene provides an improvement in antigen-specific T cells functions and/or an enhancement of the longevity of the cells.

公开(公告)号：US09914905B2

公开(公告)日：2018-03-13

申请号：US15394468

申请日：2016-12-29

Applicant: SCARAB GENOMICS, LLC

Inventor： Frederick R. Blattner ,  Balint Csorgo ,  Gyorgy Posfai

IPC: C12N1/08 ,  C12N9/10

CPC classification number: C12N1/08 ,  C12N9/1007 ,  C12N9/1252 ,  C12N15/70 ,  C12P21/00 ,  C12P21/02 ,  C12R1/19 ,  C12Y201/01037

Abstract: Reduced genome bacteria with improved genetic stability are provided. Also provided are methods of producing polypeptides using the reduced genome bacteria with improved genetic stability.